TY - T1的心脏结节病:系统回顾文献对皮质类固醇和免疫抑制疗法JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.00449 -2021欧元SP - 2100449 AU Stievenart朱利安AU - Le Guenno Guillaume盟——Ruivard Marc盟——Rieu小薇吉妮盟——安德烈,马克•AU - Grobost文森特Y1 - 2021/01/01 UR - //www.qdcxjkg.com/content/early/2021/08/26/13993003.00449 - 2021. -抽象N2 -背景心脏结节病(CS)是一种危及生命的疾病的明确建议缺乏。我们旨在回顾文献系统地对心脏结节病治疗皮质类固醇和/或免疫抑制剂以CS的更新管理。方法使用Pubmed、Embase和Cochrane图书馆数据库,我们发现原始文章皮质类固醇和/或标准免疫抑制治疗CS至少提供公平的标志整体评估的质量和分析复发率,主要心脏不良事件(锤)和不良事件。我们的方法基于棱镜语句和清单。结果我们21检索研究。意味着提供的质量评估是6.8/14(范围5 - 9)。糖皮质激素似乎对左心室功能有积极的影响,房室传导阻滞、室性心律失常。糖皮质激素,仅9(45%)研究复发(n = 351)提供的数据,代表34%的发病率(n = 119)。三个研究(14%,n = 73)提供数据狼牙棒(n = 33),代表45%的钉头槌仅仅用皮质类固醇治疗的病人。九个研究提供数据辅助免疫抑制治疗的四个研究(n = 78)提供数据CS复发,代表33%的发病率(n = 26)。局限性在于没有随机控制试验数据检索和不清楚钉头槌通过联合免疫抑制剂治疗的患者和糖皮质激素。结论糖皮质激素应开始后早期诊断,但确切的机制尚不清楚。 Studies concerning adjunctive conventional immunosuppressive therapies are lacking and benefits of adjunctive immunosuppressive therapies are unclear. Homogenous data on CS long-term outcomes under corticosteroids, immunosuppressive therapies and other adjunctive therapies are lacking.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. STIEVENART has nothing to disclose.Conflict of interest: Dr. Le Guenno has nothing to disclose.Conflict of interest: Dr. RUIVARD has nothing to disclose.Conflict of interest: Dr. RIEU has nothing to disclose.Conflict of interest: Dr. ANDRE has nothing to disclose.Conflict of interest: Dr. vincent has nothing to disclose. ER -